GlassScriptPhysician profile
David A Shearer
NPI 1659388726
$6,962.09
in general payments reported to CMS, 2019-2025
31 companies · $732 in 2025
The $732 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,173 · 2020: $861 · 2021: $979 · 2022: $1,210 · 2023: $914 · 2024: $1,092 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,478 · Education: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,478.38 |
| Education | $259.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,013.98 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,018.50 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $568.23 | 2019-2025 | |
| Lilly USA, LLC | $484.51 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $335.49 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $311.79 | 2019-2025 | |
| Ucb, INC. | $229.31 | 2019-2025 | Bimzelx |
| Genzyme Corporation | $127.16 | 2019-2022 | |
| Amgen INC. | $121.82 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $80.55 | 2022-2024 | Sotyktu |
| Helsinn Therapeutics (U.S.), INC. | $74.30 | 2019-2022 | |
| Galderma Laboratories, L.P. | $73.15 | 2020-2025 | Nemluvio |
| Leo Pharma INC. | $69.49 | 2021-2022 | |
| Kyowa Kirin, INC. | $50.29 | 2020-2023 | Poteligeo |
| Incyte Corporation | $41.73 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medline Industries LP | $35.29 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $34.12 | 2019-2025 | Cabtreo |
| Almirall LLC | $31.88 | 2021-2025 | Seysara |
| Paratek Pharmaceuticals, INC. | $27.25 | 2019-2020 | |
| Genentech USA, INC. | $25.09 | 2019 | |
| Verrica Pharmaceuticals INC. | $24.42 | 2023 | Ycanth |
| Blueprint Medicines Corporation | $24.26 | 2022 | |
| Krystal Biotech INC | $23.11 | 2023 | Vyjuvek |
| Vyne Pharmaceuticals INC. | $22.65 | 2020 | |
| Mylan Institutional INC. | $18.54 | 2023 | Hulio |
| Pfizer INC. | $18.38 | 2024 | |
| Biofrontera INC. | $18.12 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Lnhc, INC | $16.29 | 2025 | Zelsuvmi |
| Icad, INC | $15.38 | 2022 | |
| Merck Sharp & Dohme LLC | $14.50 | 2019 | |
| Epi Health, LLC | $12.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Shearer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.